Loading
CAR-T Cell Therapy Research / CRISPR and Genetic Engineering · Journal article
Nature Communications · August 11, 2026
Encouraging direction, but not yet definitive.
Tracking-seq2 is a detection method that combines exonuclease treatment and NHEJ pathway inhibition to improve sensitivity for identifying off-target CRISPR activity in primary human cells. The method shows enhanced sensitivity across multiple editor types (Cas9, Cas12a, CBEs, ABEs, PEs) and reveals individual-level genomic variation in off-target heterogeneity, suggesting a need for personalized safety assessment in clinical genome editing.
Technology development and validation study. Primary human T cells and CD34+ hematopoietic stem and progenitor cells from multiple individuals with different genomic variations. Intervention: Tracking-seq2: integration of exogenous 5′ → 3′ exonuclease treatment and non-homologous end joining pathway inhibitors with original Tracking-seq. Compared with: Current state-of-the-art off-target detection methods (specific comparators not named).
Tracking-seq2 exhibits enhanced sensitivity in profiling off-target sites of diverse genome editors including Cas9, Cas12a, cytosine base editors, adenine base editors, and prime editors Method is directly applicable to clinically relevant primary human cell types: T cells and CD34+ hematopoietic stem and progenitor cells Genomic variations drive distinct off-target heterogeneity across different individuals, highlighting necessity for personalized safety assessment
Genomic variations drive distinct off-target heterogeneity across different individuals, highlighting necessity for personalized safety assessment
Tracking-seq2 offers an improved safety-assessment tool for evaluating CRISPR off-target effects before clinical deployment, with particular relevance to T cell and HSPC-based gene therapies. The identification of individual-level heterogeneity in off-target activity supports the case for personalized pre-treatment safety screening in clinical genome editing applications.
A methodological advance in detection sensitivity for CRISPR off-target effects in primary human cells, demonstrated across multiple editor types, but without clinical outcome data or comparative effectiveness trial.
As stated by the source record.
Tracking-seq2 offers an improved safety-assessment tool for evaluating CRISPR off-target effects before clinical deployment, with particular relevance to T cell and HSPC-based gene therapies. The identification of individual-level heterogeneity in off-target activity supports the case for personalized pre-treatment safety screening in clinical genome editing applications.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Accurate detection of off-target activity in primary human cells is crucial for ensuring the safety of gene therapies, yet existing methods often lack sufficient sensitivity. To address this limitation, we develop Tracking-seq2, an advanced technology that integrates exogenous 5′ → 3′ exonuclease treatment and non-homologous end joining (NHEJ) pathway inhibitors with the original Tracking-seq. Tracking-seq2 exhibits enhanced sensitivity in profiling off-target sites of diverse genome editors—including Cas9, Cas12a, cytosine base editors (CBEs), adenine base editors (ABEs), and prime editors (PEs). Critically, Tracking-seq2 is directly applicable to clinically relevant primary human cell types, such as T cells and CD34 + hematopoietic stem and progenitor cells (HSPCs). Furthermore, our findings reveal that genomic variations drive distinct off-target heterogeneity across different individuals, highlighting the necessity for personalized safety assessment in clinical genome editing applications. Tracking-seq2 provides a robust platform for sensitive off-target detection in primary cells, with sensitivity comparable to or exceeding current state-of-the-art methods.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.